FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, [| D.C. 20549 |
|---------------|------------|
|---------------|------------|

| Check this box if no longer subject |
|-------------------------------------|
| to Section 16. Form 4 or Form 5 |
| obligations may continue. See |
| Instruction 1(h) |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* ROBIN HOWARD W | | | | | 2. Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS [NKTR] | | | | | | | | ! | Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | |
|---|--|----------|---------|---|--|---|--------|-----------------|-------------------------------|--|--|---------------|---|--|---|---------------------------------|--|--|--------------|
| ROBIN HOWARD W | | | | | | | | | | | | | | X Direc | | tor | | 10% Ov | vner |
| (Last) | (Fir | st) (N | /iddle) |) | 3 Ds | 2 Date of Forliget Transposition (Month/Dou/Month) | | | | | | | | | Office | er (give title v) | | Other (s below) | specify |
| C/O NEI | C/O NEKTAR THERAPEUTICS | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 08/17/2020 | | | | | | | | President & CEO | | | | | |
| 455 MISSION BAY BOULEVARD SOUTH | | | | | | 35, 11, 2323 | | | | | | | | | | | | | |
| 455 1115 | | | | | | | | | | | | | | | | | | | |
| (Street) | | | | | 4. If A | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| SAN | CA | . 0 | 4158 | | | | | | | | | | | X | , | | | | |
| FRANCI | SCO CF | <i>3</i> | 4130 | | | | | | | | | | | | Form filed by More than One Reporting Person | | | | orting |
| (City) | (Sta | ate) (Z | Zip) | | | | | | | | | | | | | | | | |
| | | Table | I - N | on-Deriva | tive S | Secui | rities | Ac | quire | d, Dis | sposed of | , or B | enefic | cially | Own | ed | | | |
| 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y | | | | | Execution Date | | · | Transaction Dis | | 4. Securities Acquired (A) on Disposed Of (D) (Instr. 3, 4 | | | and 5) Securi Benefi Owned | | ities For icially (D) d Following (I) (| | n: Direct or Indirect nstr. 4) | 7. Nature of Indirect Beneficial Ownership | |
| | | | | | | | | | Code | v | Amount | (A) or (D) | Price | | | rted action(s) . 3 and 4) | | | (Instr. 4) |
| Common Stock 08/17/20 | | | | | 20 | | | | S | | 11,885(1) | D | \$19. | .67(2) | 364,018 | | | D | |
| Common Stock | | | | | | | | | | | | | | | 410 | | | | by spouse |
| | | Tal | ole II | | | | | | | | osed of, | | | | Owne | d | | | |
| | | | | (e.g., pu | its, ca | alis, v | varra | ants. | optio | ons, | convertib | le sec | uritie | s) | | | | | |
| 1. Title of Derivative Security (Instr. 3) | ve Conversion Date or Exercise (Month/Day/Year) Execution Date, if any | | | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | Expir | te Exer ation D th/Day/ | | 7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | | | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Date Exerc | isable | Expiration Date | | Amoun or Numbe of Shares | | | | | | |

Explanation of Responses:

- 1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- 2. This transaction was executed in multiple trades at prices ranging from \$19.35 to \$19.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

Remarks:

Mark A. Wilson, Attorney-in-**Fact**

08/19/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

** Signature of Reporting Person

Date

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.